31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
To examine telehealth adoption and discontinuation by home health agencies (HHAs) during the COVID-19 pandemic in the context of telehealth pre-pandemic diffusion into the industry and its continued use once the pandemic abated. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 343 palliative care evaluations (for 322 unique patients), 38% were of patients who identified as African American/Black, 38% as White, 9% as Asian/Pacific Islander, and 15% as other races; 41% were of patients who identified as Hispanic/Latino (measured separately from race); 80% were of female patients; and the mean patient age was 88 years. 5 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is often underdiagnosed, especially at early stages when symptoms are mild, and patients may benefit from new and recently approved anti-amyloid therapies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Remote monitoring (RM) technology can support home-based dementia care by enabling (in)formal caregivers to monitor the health and safety of people with dementia remotely. 1 key finding →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
We found that COVID patients initially experienced substantially longer hospital stays (8.3 vs 4.6 days) and higher 30-day mortality (34% vs 5%) compared to patients without COVID. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 18,383 CM patients PS-matched to 18,383 dialysis patients, unadjusted Cox models showed dialysis transition was associated with higher risk of dementia, MCI, or combined dementia/MCI vs. CM: HRs (95%CIs) 1.40 (1.32-1.48), 1.64 (1.46, 1.85), and 1.42 (1.34, 1.49). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings highlight potential access and quality-of-care issues in PR, with implications for Medicare Advantage benchmarks. 4 key findings →
Participants: 4,965 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Informal caregivers often seek additional support. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this update, we examine a checklist for real-world evidence use in Medicare drug price negotiations under the Inflation Reduction Act, a review of health technology assessment reassessments across major health technology assessment agencies, and two complementary studies that used natural experiment approaches to explore the relationship between herpes zoster vaccination and reduced dementia risk. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In 2024, 90% of Medicare Advantage (MA) enrollees were in a plan that required prior authorization of home health care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified 11,480 beneficiaries in the IDEAS study sample and 3,008,067 in the eligible sample. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The median proportion of in-hospital LTC certification applications was 30.5% (IQR 24.5%-36.1%). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MA-PD enrollees had significantly lower utilization of PIMs than standalone PDP enrollees: a 0.7 percentage-point [95% CI: 0.5, 0.8] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia; a 3.1 percentage-point [2.6, 3.5] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia and a history of falls; and a 0.5 percentage-point [0.4, 0.6] lower prevalence of high-risk medications in older adults. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among the 1,035 patients in our dataset, 176 (17%) had a dementia diagnosis. 5 key findings →
Participants: 1,035 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 19 included studies, most used quantitative designs and secondary data. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This real-life study aims to describe and compare the characteristics of patients who do or do not receive speech therapy after a memory consultation. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There were few differences in how MA plan characteristics affected choice among older adults with and without dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Persons with dementia were significantly more likely to enter HHC directly from the community (60% vs. 37%, adjusted OR = 1.52, 95% CI = 1.50-1.53). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Dementia Datahub (https://dementiadatahub.org/) currently provides mapping, data reporting dashboards, system documentation, and public use files (available upon request) of statistics from the year 2020. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Successfully embedding technology into long-term care settings requires intentional, evidence-based community engagement strategies that address the unique needs of providers, caregivers, and persons living with dementia. 1 key finding →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 2022 revision of Japanese healthcare reimbursement removed pharmacists from the mandatory dysphagia team, despite emerging evidence of medication-related swallowing complications. 3 key findings →
Participants: 59 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated